Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acute and Short-Term Efficacy of 0.33% Brimonidine in Persistent Erythema of Rosacea: A Prospective Two-Phase Study Incorporating a Split-Face, Randomized, Placebo-Controlled Design and Objective Biophysical and Dermoscopic Assessments

NCT07431476 is registered in ClinicalTrials.gov with Istanbul Training and Research Hospital as lead sponsor.

NCT NCT07431476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07431476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acute and Short-Term Efficacy of 0.33% Brimonidine in Persistent Erythema of Rosacea: A Prospective Two-Phase Study Incorporating a Split-Face, Randomized, Placebo-Controlled Design and Objective Biophysical and Dermoscopic Assessments
Lead sponsor
Istanbul Training and Research Hospital
Phase
Phase 4
Overall status
Completed
Start date
May 1, 2025
Completion date
August 7, 2025
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rosacea, rosacea subtype 1 (erythematotelangiectatic)